Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is more severe in some specific patient groups, such as cancer patients with a mortality rate of 26.5%. The main way of protection is vaccination. In this study, we aimed to evaluate the antibody responses of our cancer patients who received two doses of the inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences. Patients over the age of 18, who had not been suspected or polymerase chain reaction-confirmed COVID-19 positive, who received two doses of the vaccine, and at least 28 days passed after the second dose, and who received at least one dose of cancer treatment before the vaccination-were included in the study. Immunoglobulin class G antibodies against the receptor binding region (S-RBD) of the spike protein S1 subunit of SARS-CoV-2 were studied. A total of 200 patients with a diagnosis of cancer were included in the study. The median time between the second dose of the Sinovac vaccine and the time of blood collection was 3.44 (3.20−3.84) months. SARS-CoV-2 antibody positivity was detected in 110 (55%)patients. The two subgroups with the highest antibody levels were gynecological cancers and breast cancers, with median 158.5 AU/ml (38.4−764.5) and 106.3 AU/ ml (61.9−162.9) levels, respectively. Antibody positivity rate was 46.8% in patients who received chemotherapy at any time between the first dose of the vaccine and the date of blood collection; and it was 73.8% in the group that did not receive chemotherapy (p < 0.001). As a result, the expected antibody response was not obtained with two doses of the Sinovac vaccine. Therefore, if the Sinovac vaccine is to be preferred for these patients, the appropriate booster time for the third dose should be determined or other vaccines, such as messenger RNA vaccines, with reported higher antibody responses should be considered.
Amaç: Medulloblastom çocukluk çağında sık görülen beyin tümörlerinden biridir. Erişkin yaşta ise çok nadir olarak görülmektedir. Bu çalışmamızda medulloblastom tanılı hastalarımızın klinik ve patolojik özelliklerini paylaşmayı amaçladık Yöntemler: 2010 Kasım ile 2020 Nisan ayı arasında medulloblastom tanısı alan 28 hasta çalışmaya dahil edilmiştir. Hasta dosya sistemin-den yaş, cinsiyet, tanı tarihi, ex tarihi, progresyon tarihi, tümör lokalizasyonu, tümör histopatolojik alt tipi, cerrahi şekli verileri kaydedildi. Hastaların 5 yıllık ortalama sağkalım ve progresyonsuz sağkalım oranları hesaplandı. Bulgular: Hastaların ortalama yaşı 32 idi. 16 hasta erkek 12 si ise kadındı. Histopatolojik özelliklerine bakıldığında 17 hasta klasik varyant, 11 hasta ise desmoplastik histopatolojiye sahipti. 15 has-tada nüks saptanırken 13 hasta nüks bulgusuna rastlanılmadı. 28 hastanın 16’sı yaşıyor 12 hasta ise ex olmuştu. Hastaların 5 yıllık OS %59,4, 5 yıllık PFS ise %42,3 idi Sonuç: Medulloblastom erişkin dönemde çok nadir olarak görüldüğü için bu hastalık ile ilgili yeterli veri bulunmamaktadır. Komplet rezeksiyon bu hastalarda sağkalım açısından büyük önem içermektedir.
Objective: There are some studies about the significance of the peripheral blood parameters in breast cancer. However, there is very few studies about prognostic importance of peripheral blood parameters in human epidermal growth factor-2 receptor (Her-2) positive breast cancer. We aimed to evaluate whether prognostic significance of peripheral blood parameters in patients Her-2 positive metastatic breast cancer with treated Pertuzumab, Trastuzumab, Docetaxel (PTD) Material and Methods: We included 56 patients with Her-2 positive metastatic breast cancer patients who were treated with PTD. We recorded patients' clinical,demographic features and we obtained peripheral blood parameters such as neutrophil-lymphocyte ratio (NLR), red blood cell distribution (RDW), mean platelet volume (MPV), lymphocyte, neutrophil after the sixth cycle of the treatment and before the treatment. We separated the patients into two groups depending on the progression status. Progression-free survival was analyzed by Kaplan-Meier statistical analysis. Results: Patients mean age was 50.7. Progression was detected in 34 patients. When we explored and compared hemogram parameters in the groups before the treatment, there wasn’t statistically any significant difference between these parameters such as neutrophil, lymphocyte, neutrophil to lymphocyte ratio, mean platelet volume, red blood cell width. In the progressive group;,while pretreatment NLR was 3.83, it was detected 2.72 after six cycle treatment and difference was meaningful ( p: 0.043). The pretreamtent MPV was 8.63, and It was 8.15 after six cycle treatment, and difference between these counts was statistically important (p: 0.006). PFS was 18.0 months in the study group. Conclusion: Peripheral blood parameters were not statistically significant in both group comparisons. In the progression group, the difference between NLR and MPV count was statistically significant after the sixth cycle of the treatment and before the treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.